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Airway responses to bronchial provocation tests are traditionally assessed with spirometry
which necessitates considerable patient co-operation. It has been shown that coughing during
bronchial provocation tests is related to the degree of bronchoconstriction which, in turn, is
independent of patient co-operation. The aim of the present study was to evaluate the utility
of coughing induced by the hypertonic histamine challenge in the differential diagnosis of
asthma in a clinically relevant patient population.
The study population consisted of 25 healthy volunteers, 30 asthmatics, and 82 non-
asthmatic subjects with respiratory symptoms due to other diseases. Hypertonic histamine
solution was administered with ultrasonic nebuliser with the challenges being videotaped.
The cough response was expressed as the cumulative number of coughs divided by the final his-
tamine concentration administered (CCR).
The geometric mean (95% CI) of CCR for asthmatics was 302 (166e562) coughs per mg/ml,
for the symptomatic controls 29.5 (20.0e43.7) coughs per mg/ml (p< 0.001) and for the
healthy controls 6.61 (3.02e14.5) (p< 0.001) coughs per mg/ml. According to the ROC curve,
the optimal cut-off point for logCCR was 2.22, with the specificity and sensitivity to detect
asthma among symptomatic subjects being 86% and 70%. Cough response to hyperosmolar chal-
lenge may be useful in the differential diagnosis of airway diseases.
ª 2008 Elsevier Ltd. All rights reserved.47174795; fax: þ358 17 172683.
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Table 1 Characteristics of the subjects
Healthy Asthmatics Symptomatic
controls
n 25 30 82
Gender
M/F 12/13 6/24 39/43
Age 42 (22e59) 48 (25e73) 47 (19e74)
Smoking
Current 10 7 14
Previous 1 12 24
Pack-years 12 (5e20) 10 (0.3e40) 16 (1.5e45)
Symptom duration
(months)
48 (4e180) 47 (0e150)
Cough during the
preceding two
weeks
4 (16%) 25 (81%)a 53 (65%)a
Atopyb 8 13 22
FEV1%
c 97 (77e116) 89 (66e118) 93 (65e122)
nZ number of subjects. Age, pack-year (Z20 cigarettes per
day for one year), FEV1 and symptom duration are expressed
as mean (range).
a Asthmatics versus symptomatic controls, p> 0.05.
b Atopy is assessed as 3 mm mean wheel diameter in skin
prick test to at least one common aeroallergen.
c Pre-bronchodilation values are shown. Predicted values are
those of Viljanen et al.37
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Traditionally the diagnosis of asthma has been based on the
measurement of airway hyperresponsiveness and reversible
bronchoconstriction1 but these are known to require con-
siderable patient co-operation especially in spirometry.
Nowadays, patients are often elderly, and those who can-
not perform spirometry are not uncommon.2,3 Therefore,
complementary methods are needed to replace the FEV1
measurement. Both pulse oximetry and observation of
wheezing with chest auscultation have been utilised as
adjunct techniques, or instead of, spirometry in young
children4e7 and in adults8 while assessing objectively the
responses during inhalation challenges.
One previously recognised sign of bronchoconstriction is
the cough induced by the different inhalation challenges.
Since this cough is independent of compliance on the part
of the patient, it could be used as a surrogate for
spirometry. We have already shown that coughing fre-
quency during airway challenge with histamine is closely
related to the degree of induced bronchoconstriction.9 In
addition, the indirect inhalation challenges, such as manni-
tol and hypertonic saline solution challenge, induce fre-
quent coughing which already has clinical implications.10
However, this cough is not solely dependent on the pres-
ence of bronchoconstriction.
One problem encountered in the diagnosis of asthma is
its differentiation from several pulmonary and cardiac
disorders whose probability increases in parallel with aging,
for example, overt heart failure,11 COPD,12 sarcoidosis,13
gastroesophageal reflux and postnasal drip syndrome.14
Therefore, the diagnostic value of a hyperresponsiveness
test cannot be reliably determined with a study population
consisting only of young, steroid-naı¨ve asthmatics and
healthy, non-symptomatic subjects.9 In order to create
a scenario corresponding to an unselected outpatient clinic
material, both asthmatic subjects and subjects with other
respiratory co-morbidities common in the adult population
were recruited.15 The aim of this study was to evaluate the
utility of hypertonic histamine challenge (HHC) induced
cough in the differential diagnosis of difficult-to-diagnose
asthma in a real-life clinical setting.
Materials and methods
A detailed description of the study population and the
challenge has been published previously, and this is another
analysis of the same data set.15 The previous report con-
cerned the role of HHC induced airway hyperresponsiveness
in the differential diagnosis of asthma in a clinically repre-
sentative, symptomatic group of subjects. The present
report describes the role of cough responses in the same
patient population.
Subjects
A total of 138 subjects took part in this study. According to
the GINA guidelines,16 a total of 31 of these subsequently
recruited subjects were confirmed as having asthma. One
of them had intermittent, 26 had mild persistent and 4
suffered from moderate persistent asthma.15 The coughrecording succeeded in 30 subjects. The symptomatic con-
trol group consisted of the following subjects: 26 subjects
with symptoms suggestive of asthma but without objective
evidence of reversible airway obstruction in at least 6
months follow-up, 7 subjects with COPD,17 15 patients
with parenchymal lung disease,18 21 subjects with persis-
tent rhinitis,19 and 13 subjects with NYHA I-II chronic heart
failure.20 In addition, 25 healthy, non-symptomatic sub-
jects were recruited from the personnel of Kuopio Univer-
sity Hospital. Further details of the groups are described
in Table 1.
The exclusion criteria for all subjects were FEV1< 65%,
severe coronary heart disease, and severe heart failure or
arrhythmia tendency. The use of oral or inhaled corticoste-
roid preparations was not allowed during the four weeks
prior to the study. The dose of oral steroids in subjects
with parenchymal lung diseases had to be less than 10 mg
per day. Before the inhalation challenge test, the patients
refrained from taking short-acting b2-agonists for 6 h, long
acting b2-agonists and tiotropium for 48 h, anticholinergics
for 8 h, antihistamines and leukotriene receptor antago-
nists for 3 days. In addition, the subjects were asked to
avoid smoking, coffee and vigorous exercise during the
study day. The Finnish National Agency of Medicines and
the Institutional Ethics Committee approved this study.
All subjects provided their informed written consent for
participation in the study.
Protocol
An experienced respiratory physician examined all the
subjects. Thereafter, spirometry with bronchodilation test
(Sensor Medic Vmax 22D, Sensor Medics Corporation, Yorba
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Figure 1 The coughs/concentration ratio (the cumulative
number of coughs during the entire challenge divided by the
achieved final histamine concentration) of asthmatic subjects
was statistically significantly higher than that of the healthy
or the symptomatic controls (p< 0.001, respectively). The
horizontal lines express geometric means.
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aeroallergens (Soluprick SQ, ALK-Abello´, Ho¨rsholm, Den-
mark) were performed. Atopy was defined as at least a 3-
mm wheal reaction to any of the allergens.22 The symptom
questionnaire was completed under the guidance of a re-
search nurse. During the same day, the hypertonic hista-
mine challenge was performed. The subjects with
asthma, suspicion of asthma, COPD, and rhinitis performed
ambulatory PEF monitoring for two weeks, three times
daily. The response to 0.2 mg salbutamol (Buventol Easy-
haler, Orion Ltd., Orion Pharma, Helsinki, Finland) was
assessed every morning during the second week.23
Hypertonic histamine challenge
Three technically acceptable forced expiratory manoeuvres
(model M9449; Medikro Ltd; Kuopio, Finland) were per-
formed, and the largest FEV1 was used as the baseline
value. A portable ultrasound nebuliser with a measured
output of 0.44e0.48 ml/min (Omron U1; Omron LTD; Tokyo,
Japan) was administered. The challenge was started with
inhalation of hypertonic phosphate buffered saline aerosol
for 2 min. After a 90-s follow-up period, two technically
satisfactory forced expiratory manoeuvres were per-
formed. In the subsequent inhalations, histamine diphos-
phate (Histamini phosphas; Ph.Eur., University Pharmacy;
Helsinki, Finland) was dissolved in hypertonic phosphate
buffered saline solution at doubling concentrations from
0.0075 to 4.0 mg/ml. The osmolality of the hypertonic his-
tamine solutions was 1522e1577 mOsm/kg. The challenge
was continued until the FEV1 had fallen 20% from the
baseline value, or up to the inhalation of the final solution.
The airway responsiveness to hypertonic histamine was ex-
pressed as the provocative concentration of histamine to
induce a 20% fall in FEV1 (PC20), which was estimated by
linear interpolation. For statistical analyses, an arbitrary
concentration of 8 mg/ml was used as the PC20 value in
those subjects who did not respond to the final histamine
concentration of 4 mg/ml. The coughs were manually
recorded during the challenge by a research nurse. The ses-
sion was video recorded to enable subsequent cough count-
ing to determine the test reliability.
Statistical analysis
The cumulative number of coughs during the entire chal-
lenge was calculated. This value was divided by the
achieved final histamine concentration to obtain the
coughs/concentration ratio (CCR), this being expressed as
coughs per mg/ml. Coughing frequency (Cf) was defined as
the cumulative number of coughs divided by the cumulative
duration of the observation period, and it was expressed as
number of coughs per minute (maximum 38.5 min consist-
ing of 12 nebulations). To exclude the possible cough-
provoking effect of bronchoconstriction, we calculated
the mean Cf at that stage of the challenge when the fall
in FEV1 was <5% from the baseline value (Cfunder5).
KolmogoroveSmirnov test was used for normality test-
ing, and logarithmic transformations of cough variables and
PC20 values were used in the statistical analyses. The values
are expressed as geometric mean (95% CI) if not otherwise
stated. The differences in cough responses between groupswere evaluated by using one-way ANOVA with Dunnett’s
t-test and with the Bonferroni correction when needed.
Receiver operator characteristic (ROC) curves were con-
structed for all of the cough variables and univariate Z-
score test was obtained utilising the area under curve
(AUC) values to determine the index with the best discrim-
inative power. Into the latter analysis, asthmatic and symp-
tomatic control groups were included. Possible effects of
confounding factors on utility of cough variables and on di-
agnostic value of CCR were evaluated by logistic regression
analysis. Differences in cough frequency between groups
were assessed with Chi square test. A p-value of <0.05
was considered to be statistically significant. All analyses
were carried out using SPSS for Windows 14.0 (SPSS Inc.,
Chicago, USA).
Results
The coughs/concentration ratio (CCR) for asthmatics was
302 (166e562) coughs per mg/ml, for the symptomatic
controls 29.5 (20.0e43.7) coughs per mg/ml and for the
healthy subjects 6.61 (3.02e14.5) coughs per mg/ml. The
CCR of asthmatic and symptomatic groups differed statis-
tically significantly from each other and from CCR of the
healthy subjects (both p< 0.001) (Fig. 1). The values of
Cfunder5 of asthmatics (17.8 (11.5e26.9) coughs/min) were
statistically significantly higher than those of the healthy
subjects (6.31 (3.47e11.5) coughs/min, pZ 0.016), but
did not differ from those of the symptomatic individuals.
CCR values of different symptomatic subgroups are
expressed in Table 2.
The univariate Z-score test showed that the AUC of CCR
was 0.850, this being statistically significantly larger than
those of the Cf and Cfunder5 variables (data not shown).
Therefore, further analysis of the results concentrated on
CCR values. The ROC curve for the logCCR determined
from the videoed coughs indicated that 1.84 (area under
the curve 0.977, p< 0.0001) represented the optimal cut-
off point for logCCR to separate asthmatic subjects from
Table 2 Coughs to concentration ratio to different
diagnostic subgroups expressed as geometric mean with
95% confidence interval
Group n Geometric
mean
95% CI p
Asthma 30 302 166e562 p< 0.001
Suspicion of asthma 26 34.7 19.1e61.7 pZ 0.315
COPD 7 69.1 18.6e251 p< 0.001
Parenchymal
lung disease
15 11.5 4.07e32.4 p< 0.001
Rhinitis 21 49.0 19.5e120 p< 0.001
Cardiac failure 13 24.0 8.71e64.6 0.021
Healthy non-smokers 15 6.31 1.78e22.4 p< 0.001
Healthy smokers 10 6.92 2.34e20.4 p< 0.001
nZ number of the subjects. p< 0.05 is considered statistically
significant in comparison of asthmatic subjects to other
separate subgroups.
1382 M. Purokivi et al.healthy controls with sensitivity of 80% and specificity of
96%. Moreover, 2.22 would be the optimal cut-off point
for logCCR to separate the asthmatic subjects from the
symptomatic control group with a sensitivity of 70% and
specificity of 86% (Fig. 2).
The logistic regression analysis was conducted between
the asthmatic subjects and the symptomatic control group
consisting of subjects with symptoms suggestive of asthma
but without objective evidence of reversible airway ob-
struction in at least 6 months follow-up, and of subjects
with COPD, parenchymal lung disease, persistent rhinitis,
and chronic heart failure. The analysis confirmed that CCR
independently had a good diagnostic accuracy in the
differential diagnosis of asthma (p< 0.001). It also revealed
that smoking, gender, atopy and baseline FEV1 had no1.00.80.60.40.20
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Figure 2 ROC curve of the coughs/concentration ratio. If
one wishes to compare asthmatic subjects to symptomatic
controls, 2.22 is the optimal cut-off point. The area under
the curve is 0.850.significant confounding effect on diagnostic utility of cough
measurements.Discussion
As far as we are aware, this is the first study to evaluate the
feasibility of using airway challenge induced cough in the
differential diagnosis of asthma in a clinically relevant,
unselected patient population. In agreement with our
previous report,9 the CCR of the asthmatic subjects was
statistically significantly higher than that of the healthy
subjects. Furthermore, the CCR of the asthmatic subjects
was also higher than that of the symptomatic subjects
who had asthma-like symptoms due to other respiratory
or cardiac disorders. These results suggest that hypertonic
histamine challenge induced cough could be utilised in
the differential diagnosis of asthma. In addition, the inde-
pendence of challenge induced cough from patient’s effort
and co-operation suggest that it has benefits over
spirometry.
This study showed that CCR as a marker of cough
independently exhibited a good prognostic value in the
differential diagnosis of asthma. In agreement with our
previous report, the cough response distinguished the
asthmatic subjects from the healthy controls with a speci-
ficity of 96% and a sensitivity of 80%.9 Moreover, if one re-
lied only on cough measurements then the specificity and
sensitivity to separate the asthmatics from the heteroge-
neous symptomatic control group were 86% and 70%, re-
spectively, which is well achieved in this clinically very
demanding patient population. In our recent study utilising
spirometrically assessed PC20, the sensitivity of the HHC
was 81% and the specificity was 70% with the cut-off value
0.83 mg/ml in this same study population.15 Methacholine,
perhaps the most popular airway challenge in assessing
airway hyperresponsiveness nowadays, has shown slightly
better values for sensitivity (87.5e91%) and specificity
(86.7e90%).24,25 However, the patient material in metha-
choline studies may not have corresponded to the real-
life clinical situation as well as that of the present study
where the symptomatic controls reported frequently as
much cough as the asthmatic subjects, for example. In Fin-
land most of the asthma diagnoses are set in primary care
as this is the intention of the National Asthma Pro-
gramme26; the reason why the patients are referred to
a specialist in a tertiary referral centre is almost invariably
due to the diagnostic difficulties. Both direct27 and indi-
rect2,28 inhalation challenge tests have been shown to
have limited value in the differential diagnosis of mild
and atypical asthma in Finnish outpatient clinic material.
This is partly due to the high prevalence of mild to moder-
ate airway hyperresponsiveness which is known to be asso-
ciated with many common respiratory diseases13,29e31 in
the adult population. It is possible that examination of
hypertonic histamine challenge induced cough may help
to overcome some of the present diagnostic problems.
The present results emphasize the utility of CCR over
other previously introduced cough variables in the differ-
ential diagnosis of respiratory diseases.9 The CCR occurring
in association with hypertonic histamine challenge consists
of two components, the bronchoconstriction induced cough
HHC induced cough in diagnosing asthma 1383and the cough induced by the elevated osmolarity of the
epithelial lining fluid.32 The bronchoconstriction induced
cough is a physiological response common to both healthy
and asthmatic subjects. On the contrary, cough induced
by hypertonicity is a pathological feature associated with
asthma. The sensitivity to histamine is elevated in the
smooth muscle cells of asthmatics compared to those of
the controls. This sensitivity leads to bronchial obstruction
and stimulation of coughs at lower histamine concentra-
tions in asthmatics. At the same time, the sensitivity of
cough receptors to a hyperosmolar stimulus is elevated
among asthmatic subjects but is not disturbed among con-
trols with respiratory symptoms due to other causes.9,10
Hypertonic histamine challenge induced cough response
is independent of the patient’s effort and co-operation. In
line with report of Toelle et al., we have demonstrated that
HHC is a safe and well-tolerated challenge method.33,34 This
suggests that HHC induced cough could be utilised in diag-
nosing asthma in patients with poor ability to be subjected
to spirometry which is often the case with small children
and elderly subjects. However, in agreement with an earlier
report evaluating children, we were not able to predict the
magnitude of the challenge induced bronchoconstriction
with the number of coughs alone (data not shown).6
To further improve the feasibility of using hypertonic
histamine challenge, spirometry should be replaced by
some other safety measurement. In previous attempts to
simplify protocols for inhalation challenges, several non-
invasive techniques requiring only passive co-operation
have been utilised. For example, the pulse oximetry and
chest auscultation are interesting, since they can be used in
the inhalation challenge test conducted in primary care,
even in field studies. The decrease of the arterial oxygen
level and its association to changes in airflow measure-
ments during methacholine challenge is also well docu-
mented.8 Though the sensitivity of the pulse oximetry is
reported to be at least as good as that of the FEV1 in recog-
nising bronchoconstriction, it is not recommended to be
used as the only safety measurement.5 Chest auscultation
has been utilised successfully in detecting challenge in-
duced wheezing as a challenge end-point in children.6,35
However, a significant fall in FEV1 may occur without any
wheezing, suggesting that the chest auscultation is also
not sufficient when used alone. A recent study concerning
the feasibility of using methacholine challenge in children,
supported the combination of auscultation, follow-up of
coughing and measurement of oxygen saturation in assess-
ing the challenge end-point.36 This kind of combination
might be a useful option also in the context of hypertonic
histamine challenge, and deserves further evaluation.
In conclusion, the present study demonstrates that the
cough response to hyperosmolar airway challenges can be
utilised in the differential diagnosis of asthma. Since this
response is independent of patient co-operation, it may be
especially useful among subjects who cannot perform
spirometry in a reliable manner.Conflict of interest
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